Pediatrix Medical Group, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mark S. Ordan
- Full Time Employees
- 6,575
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 1301 Concord Terrace Sunrise FL United States 33323
- IPO Date
- Sep 20, 1995
- CIK
- 0000893949
- Website
- pediatrix.com
- Similar Companies
- Business
- Pediatrix Medical Group, Inc. (NYSE: MD) is a physician-led provider of specialized health care services for women, babies, and children across the United States. The company offers maternal-fetal medicine, obstetrical hospitalist services, obstetrics and gynecology care; neonatology including neonatal intensive care units (NICUs), newborn nursery services, and newborn hearing screens; and more than 20 pediatric subspecialties such as cardiology, pulmonology, neurology, gastroenterology, hematology, infectious disease, intensive/critical care, emergency medicine, surgery, and hospitalist services; complemented by telemedicine solutions, telehealth, and evidence-based clinical research support. Pediatrix-affiliated clinicians, numbering approximately 4,400 including over 2,600 physicians, deliver coordinated care in hospital settings and office-based practices, partnering with nearly 400 hospitals and health systems across 36 to 37 states. Founded in 1979 and headquartered in Sunrise, Florida, the company focuses on high-quality, patient-centered outcomes through investments in research, education, quality improvement, safety initiatives, and advanced clinical data utilization. In recent strategic developments, Pediatrix completed a portfolio restructuring in 2024-2025 by divesting its anesthesiology and radiology medical groups as well as its primary and urgent care clinics to refocus on core hospital-based services in neonatology, maternal-fetal medicine, pediatric intensive care, and obstetrics. The company transitioned to a hybrid revenue cycle management model, enhancing collection activity and operational efficiency, which contributed to improved free operating cash flow of $147 million and reduced leverage to 1.1x as of September 30, 2025. Additional changes include leadership transitions with Jim D. Swift, M.D., as CEO, a $250 million share repurchase authorization in August 2025, an S&P credit rating upgrade to 'BB' in November 2025, and raised full-year adjusted EBITDA guidance to $270-$290 million amid targeted small acquisitions in NICUs, maternal-fetal medicine, and obstetric hospitalist operations. These initiatives support same-unit revenue growth of 6.9% year-to-date in 2025 and position the company for low-single-digit volume expansion and modest reimbursement increases.
Company News
Pediatrix Medical Group (MD) Upgraded to Buy: Here's What You Should Know
Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock
What Pediatrix Medical Group (MD) Said on Its Q3 Earnings Call
Pediatrix Medical Group, Inc. (MD) Q3 2026 Earnings Call Transcript
Pediatrix Medical Group (MD) Beats Q3 Earnings and Revenue Estimates
Pediatrix Medical Group Reports Third Quarter Results
Pediatrix Medical Group 2026 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 29, 2026
Why Pediatrix Medical Group (MD) is a Top Growth Stock for the Long-Term
HB Wealth Expands Into Texas With Experienced Three-Advisor Team
Can Pediatrix Sustain Growth Despite Lower Patient Volumes?
Engineers Gate Manager LP Lowers Stock Position in Pediatrix Medical Group, Inc. $MD
Why Pediatrix Medical Group (MD) is a Top Momentum Stock for the Long-Term
Sinopharm Group (OTCMKTS:SHTDY) and Pediatrix Medical Group (NYSE:MD) Financial Survey
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?
Pediatrix Medical Group (MD) is a Top-Ranked Growth Stock: Should You Buy?
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock
Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio
Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock
Pediatrix Medical Tops Q2 Earnings on Better Cash Collections